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Abstract
Maternal-fetal cellular trafficking is the bidirectional passage of cells between the fetus and mother during pregnancy. The
presence of fetal cells in maternal circulation, brain, and muscles is known as fetal microchimerism. During pregnancy, fetal
cells can be obtained from the mother’s blood for prenatal diagnosis of the fetus. Furthermore, it has been confirmed that fetal
microchimerism persists decades later in women who have been pregnant. Investigation of the long-term consequences of fetal
microchimerism is a frontier of active study, with preliminary results pointing to both beneficial and adverse effects. This review
will examine the relevant literary information on fetal microchimerism during pregnancy and provide current knowledge regarding
the long-term effects of naturally acquired fetal microchimerism.
Introduction
Microchimerism is the presence of two genetically distinct cell populations in the same individual. Foreign
cells and DNA are found in an individual’s plasma or
tissues that originated from a genetically different individual. Naturally acquired microchimerism is commonly
observed and results from the maternal-fetal exchange
of cells and DNA during pregnancy. (Gammill & Nelson
2010) In pregnancy, there is transplacental two-way
trafficking of living fetal cells from the fetus into the
maternal circulation, and cells from maternal circulation
impart in the fetus. (Naik, Shrivastava, Suryawanshi, &
Gupta 2019) This paper provides an overview of the
role of fetal cell microchimerism in autoimmune and
cancerous diseases. The mechanisms by which fetal microchimerism is believed to modulate the protection
against cancer or tumor progression will be discussed,
along with future research directions.

Fetal microchimerism has been reported in the peripheral blood of women in cellular subsets, including lymphoid-lineage and myeloid-lineage cells.An experiment was
done to evaluate microchimerism in CD66b sorted granulocytes. Granulocytes were isolated from the peripheral
blood of healthy women. CD66b+ cells were then isolated
by fluorescence-activated cell sorting, and a panel of polymorphism-specific quantitative assays was employed to
investigate the presence of fetal and maternal microchimerism. One-third of the women tested positive for at least
one form of microchimerism. 40% had maternal microchimerism compared to 15% who had fetal microchimerism.
The maternal and fetal origin CD66b+ cells are strong evidence for an active microchimeric hematopoietic stem and
progenitor cell niche. Higher proportions of women might
test positive for even larger quantities of microchimerism if
more sensitive assays were available. (Sunku, Gadi, Lacoste,
Guthrie, & Nelson, 2010)

Methods
This document was written by researching peer-reviewed
scholarly articles and medical journals to assess the
newest research and methods in fetal microchimerism.
The information and data were gathered from numerous sources, including databases such as Google Scholar,
Touro Library, The National Center for Biotechnology
Information, and The National Institute of Health. Keyphrases searched included, “fetal microchimerism,” “the
effects of fetal microchimerism,” and “fetal microchimerism in autoimmune disorders.” All the content was
carefully selected, compared, and analyzed to assure its
validity and determine the articles’ standpoint.

Fetal DNA in Maternal Plasma During Pregnancy
Another study was undertaken to evaluate fetal DNA
in maternal plasma and urine. DNA was isolated from
plasma and urine samples of 80 pregnant women, ranging
from 7 to 40 weeks of gestation. Their DNA underwent
amplification for Y specific chromosome DNA via a nested polymerase chain reaction. The postpartum analysis of
fetal gender showed that 25 women carried female fetuses and 55 male fetuses. Among the 55 women bearing
male fetuses,Y chromosome‐specific signals were detected in 96% of their plasma and 38% of their urine samples.
(Al-Yatama et al., 2001) The detection of fetal sex chromosomes with Y-chromosome-PCR has a specificity of
100% and a sensitivity of 96%, which increases along with
gestational age.This minor lack of sensitivity explains why
Y-chromosome signals were only located in 96% of the
plasma of pregnant women. (Rijnders et al.) The analysis
of their results with respect to gestational age showed no
significant difference in the Y chromosome‐specific DNA
detection. These results showed that fetus‐specific DNA
was detected in the maternal plasma by nested PCR. (AlYatama et al., 2001)
Fetal DNA is present in low concentration in maternal
plasma increasing throughout pregnancy with a 0.1% increase each week from 10 to 20 weeks’ gestation, followed

Fetal Microchimerism
Microchimerism is the fetus’s cell legacy after pregnancy.
Fetal stem cells can leave the fetus and migrate across
the placenta to engraft in the maternal bone marrow and
other tissues. The transfer of fetal progenitor stem cells
begins four or five weeks after fertilization and continues
throughout the pregnancy. This form of microchimerism
occurs in both male and female embryos, but the detection of male microchimerism in maternal tissue is easier
to detect due to the unique presence of Y-chromosome
in the women. (Miech, 2010)
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by a 1% increase each week from the 21st week until term.
(Taglauer et al.) Clinical tests have tried to capitalize on
this DNA to identify the baby’s sex, determine whether
the child and mother have Rh incompatibility, and identify
chromosomal disorders. (LeslieDec, et al. 2017)
Many early investigations of fetomaternal cell trafficking sought to develop methods whereby noninvasive
prenatal diagnosis of genetic disorders could be achieved.
(Gammill & Nelson 2010) Noninvasive testing would
ameliorate the risk of fetal miscarriage associated with
current invasive procedures such as amniocentesis. This
non-invasive prenatal test is a blood test, and between
25 and 42.5 milliliters are collected. (Bianchi, Williams,
Pelletier, Klinger, & Shuber 1996) The main conditions for
which prenatal diagnosis is considered are monogenic diseases, when the causation of the disease results from one
gene, and therefore, is easier to detect and obtains conclusive results. Fetal DNA circulates in a high background
of maternal DNA and is isolated and amplified using polymerase chain reaction technology. However, even after
that, maternally inherited fetal alleles are very difficult to
identify from maternal plasma, therefore, scientists have
focused on the detection of paternally inherited fetal alleles that are not present in the maternal genome. The
diagnosis of autosomal dominant diseases transmitted by
the father could be made noninvasively. Also, by detecting
the paternally inherited fetal alleles, one can exclude the
fetal inheritance of autosomal recessive diseases. The discovery of free cellular fetal DNA in maternal plasma has
offered new approaches for noninvasive diagnosis, and
fetal isolation analysis is now possible. (Lun et al., 2008)
Fetal DNA in Maternal Plasma After Pregnancy
Microchimerism occurs as a result of the fetomaternal
transfusion of blood cells across the placenta during pregnancy. After delivery, once the placenta has been expelled,
fetal-origin cells should hypothetically depart from the
maternal circulation. Nevertheless, studies of women who
had given birth to a male child showed a high incidence
of male cells in their blood after delivery. Additionally,
some women have displayed male cells in their tissues
up to 27 years postpartum after having birthed a male
child. This event can be interpreted to mean that fetal
cells transferred from the fetus to the mother during
pregnancy established permanent microchimerism in the
maternal body.This permanency was reported in 30–50%
of women who gave birth to a male child. (Sato, Fujimori,
Sato, & Ohto, 2008)
There is an increased fetal-to-maternal transfer of progenitor cells during an abortion procedure as the placenta is being destroyed. Maximized fetal cell trafficking
68

following a medical abortion was confirmed in an in vivo
model. Since the embryonic circulatory system is established in the first trimester of pregnancy, there is a greater
chance for the transfer of a larger number of progenitor
T cells during the first-trimester termination of pregnancy. Therefore, women who had an elective abortion in
their first or second trimester have a greater tendency
towards fetal microchimerism. (Miech, 2010)
Male microchimerism in women without sons and the
correlation of microchimerism to prior pregnancy history
was researched.Y-chromosome-specific quantitative PCR
was used to test peripheral blood mononuclear cells of
120 women. Women were categorized into four groups
based on their pregnancy histories. Group A was nulligravid and displayed 10% male microchimerism, Group B
had induced abortions and displayed 57%, Group C had
spontaneous abortions and displayed 22%, and Group
D had only daughters and displayed 8%. Male microchimerism prevalence was the greatest by a significant
amount in those with induced abortions. Other possible
sources of male microchimerism, such as those obtained
in Groups A and D, include unrecognized spontaneous
abortion or a vanished male twin. (Yan et al., 2005)
Autoimmune Effects on The Mother
It has been theorized that the persistence and abundance
of fetal microchimerism are dependent on numerous factors, including the immunogenetic relationships between
mother and fetus, and perhaps between and preexisting
inhabitants of the maternal system, from her mother or
previous children. (Gammill & Nelson 2010)
Fetal microchimerism, a form of trans-placental stem
cell transplant, helps to explain the etiology, diversity of
tissue pathology, predilection for females, and increase in
the annual incidence of autoimmune diseases in women.
(Miech, 2010) Fetal stem cells can differentiate into
mature and competent cells, such as lymphocytes and
monocytes. Fetal cells in maternal circulation or tissues
may mediate a graft vs. host disease, which can lead to the
development of autoimmune diseases. Women comprise
80% of people with autoimmune diseases. Researchers
have begun investigating the association of micro-chimerism with autoimmune diseases that predominately affect
women. (Naik, Shrivastava, Suryawanshi, & Gupta 2019)
Fetal microchimeric cells in maternal tissues led to the
discovery of a positive correlation between fetal microchimerism and autoimmune diseases in women. Progenitor
cells in the fetal immune system, such as T cells, monocytes, macrophages, lymphocytes, and NK cells, are among
the many fetal cell types that can be transferred to maternal tissues. In maternal tissues, the fetal microchimeric
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progenitor immature T cells are capable of self-renewal,
proliferation, and differentiation. Progenitor cell activation
can result in the production of autocrine and paracrine inflammatory responses in autoimmune diseases. Triggering
agents that activate these fetal microchimeric immune cells
to attack the maternal host cells resulting in autoimmune
disease have not yet been identified. Suspected triggers
include viral or bacterial agents, abnormal localized tissue
protein, and drugs. Microchimerism in affected tissues is
more likely to be abundant in women with autoimmune
diseases than in women with non-autoimmune diseases.
(Miech, 2010)
Pregnancy alters symptoms of autoimmune diseases.
The maternal immune system develops a tolerance to
the fetus, and the suppression of the maternal response is
lifted postpartum. Fetal tolerance may explain why some
autoimmune disease symptoms decrease during pregnancy in some women. (Boddy, Fortunato, Sayres, & Aktipis,
2015) Autoimmune diseases are often repressed during
pregnancy and exasperate postpartum. It was then hypothesized that fetal cells in maternal circulation might be
important in influencing autoimmune disease in pregnancy
and postpartum. (Ando, Imaizumi, Graves, Unger, & Davies,
2002) Systemic sclerosis provided the first evidence for
the involvement of fetal microchimerism with autoimmune diseases. Patients frequently had fetal cells not only
in peripheral blood, but also in skin lesions. The hyperthyroidism of Graves’ disease frequently abates during pregnancy and exacerbates after childbearing. (Ando, Imaizumi,
Graves, Unger, & Davies, 2002) Between 43 and 75% of
patients with rheumatoid arthritis exhibit amelioration of
some or all their rheumatoid arthritis symptoms during
pregnancy. Additionally, in rheumatoid arthritis patients,
symptoms tend not only to show improvement during
pregnancy, but an exacerbation of symptoms postpartum.
Correspondingly, the rate of relapse declines with pregnancy in women diagnosed with multiple sclerosis, with the
lowest rate in the third trimester. Relapse rates return to
pre-pregnancy levels postpartum. This framework suggests
that a contributor to autoimmune disease development
may be the maternal immune response to the presence of
fetal cells that invade maternal tissues. (Boddy, Fortunato,
Sayres, & Aktipis, 2015)
The risk of developing an autoimmune disease in parous
women is higher after the first year postpartum. Fetal cells
in the thyroid may contribute to thyroid cancer risk or
susceptibility to other thyroid diseases. Current research
suggests an association with postpartum thyroid tissue
and thyroid diseases. Fetal cells are more abundant in the
thyroid tissue and blood of women with Graves’ disease
and Hashimoto’s thyroiditis, compared to healthy controls.

Also, the risk of autoimmune disease in parous women
is significantly higher after the first year postpartum. This
knowledge suggests that the presence of fetal cells in the
thyroid is associated with a maternal disease rather than
health. (Boddy, Fortunato, Sayres, & Aktipis, 2015)
Autoimmune thyroid disease affects reproductive-aged
women. It commonly initiates or exacerbates postpartum,
and so the involvement of fetal microchimerism was suspected.Autoimmune thyroid disease does have e a profound
relationship with pregnancy.Autoimmune thyroid disease involves autoimmune antigens, such as the TSHR,Tg, and TPO.
Placental immune suppression during pregnancy lessens the
activity of autoimmune thyroid disease, as seen in the remission of Graves’ disease. However, exacerbation of preexisting autoimmune thyroid diseases or initiation of autoimmune thyroid disease is also common postpartum. Increased
titers of thyroid autoantibodies have been observed in the
postpartum. Graves’ disease has also been shown to be
most markedly suppressed by pregnancy itself, but; however,
up to 60% of Graves’ disease patients of childbearing age
have been reported to develop this disease within one year
of delivery. (Ando & Davies, 2003)
Cancerous Effects on the Mother
During pregnancy, fetal cells enter the maternal body,
cross the placenta, and are found frequently in the maternal lung. It was generally accepted that the fetal cells
in the lung were passing through the mother’s pulmonary
circulation; however, the presence of fetal cells in the lung
shows an association with cancer. A study reported higher levels of male DNA and significantly more fetal cells in
the lung and thymus tissue in the diseased lung compared
to healthy bone marrow from the same person. (Boddy,
Fortunato, Sayres, & Aktipis, 2015) Fetal cells have also
been detected as clusters in lung tumors in women decades after pregnancy. Their tumor frequency was higher
in lung tumors than in the healthy surrounding lung tissue.
The fetal cells may be recruited from the bone marrow
to the tumor sites where they assumed their role in
immunosurveillance and tissue repair. (Naik, Shrivastava,
Suryawanshi, & Gupta 2019)
Fetal cells are frequently found in normal breast tissue
postpartum women.The research presents a complicated
picture of fetal cell’s role in breast cancer. Fetal cells are
found less the tissue and blood of women with breast
cancer compared to healthy controls. (Boddy, Fortunato,
Sayres, & Aktipis, 2015) It was reasoned that naturally
acquired allogeneic immune cells in the form of fetal microchimerism might correlate with protection from the
development of breast cancer. Fetal microchimerism was
found in higher quantities in healthy women compared
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to breast cancer patients, 43% to 14%, respectfully. This
shows a correlation between the role of fetal allogeneic
cells as malignant cell immune surveillance and protection
from breast cancer. (Gadi & Nelson, 2007)
Reduced risk of breast cancer is recognized among
parous compared to nulliparous women. Eighty-two
women were tested for male DNA in peripheral blood,
presumed from a prior pregnancy with a male fetus. Fortyseven of the subjects were healthy, and 35 had breast cancer.The levels of male DNA were determined by real-time
PCR for a Y chromosome-specific gene in DNA extracted
from peripheral blood mononuclear cells. Fetal microchimerism was found in 43% of healthy women and 14% in
women with breast cancer.These findings suggest that allogeneic fetal microchimerism may contribute to a reduction
in the risk of breast cancer. (Gadi & Nelson, 2007)
Through the evolutionary history of fetal microchimerism in the maternal body, it is possible that it now has
a role in normal breast tissue physiology. The maternal
mammary gland hosts stem cells that contribute to the
development of normal breast tissue and can be transferred to the neonate during lactation. Mouse fibroblast
fetal cells have been shown to differentiate into mammary
epithelioid cells when exposed to lactation hormones in
vitro, and a functional mammary gland has been generated
from a single stem cell in a pregnancy mouse model. This
suggests that fetal progenitor cells play a role in breast
morphology and maternal milk supply. (Boddy, Fortunato,
Sayres, & Aktipis, 2015)
Pregnancy at older ages has been linked to risk for
ovarian cancer. Given the data that microchimeric cells in
parous women decline overtime after pregnancy, and that
ovarian cancer develops most commonly in postmenopausal women, fetal microchimerism may play a protective role in ovarian cancer as well. (Naik, Shrivastava,
Suryawanshi, & Gupta 2019)
Neurological Effects on the Mother
It was unknown whether fetal cells, which are capable of
crossing the placental barrier to enter maternal blood,
could also cross the blood-brain barrier and enter the
maternal brain. To determine if fetal cells could enter the
maternal brain during pregnancy, female wild‐type mice
were crossed with green mice.Their offspring ubiquitously expressing the enhanced green fluorescent protein.
Green mouse fetal cells were found in the maternal brain,
and quantitative real‐time PCR of genomic DNA for the
enhanced green fluorescent protein gene showed that
more fetal cells were present in the maternal brain for
weeks postpartum than on the day of birth. After an excitotoxic lesion to the brain, more fetal cells were detected
70

in the injured region. For weeks postpartum, enhanced
green fluorescent protein‐positive green mouse fetal
cells in the maternal brain were found to adopt locations,
morphologies, and expression of immunohistochemical
markers indicative of astrocytes, neurons, oligodendrocyte, and macrophage-like cell types. The expression of
morphological and histochemical characteristics of these
cells was confirmed on the identification of fetal cells in
the maternal brain by Y chromosome fluorescence hybridization. The characterization of these cells that allow
them to cross both the placental and blood-brain barriers and to target the injured brain may improve selection
procedures for isolation of stem or progenitor cells for
brain repair by infusions. (Tan et al., 2005)
Several studies have found male DNA in human and maternal mouse brains, but the function of these cells is not
entirely known. One study found that fetal cell DNA in numerous regions of the maternal brain, even decades after
the woman had birthed a son, suggesting that fetal microchimerism in the human maternal brain may be long-lasting.
(Boddy, Fortunato, Sayres, & Aktipis, 2015) A team led by
autoimmunity researcher, J. Lee Nelson sought to discover
how leftover fetal cells affect the brain. They took samples
from autopsied brains of 59 women. Male DNA evidence
was found in the brains of 63% of the participants.The male
DNA was scattered across several brain regions. Studies
have hypothesized that the risk of Alzheimer’s disease increases with an increasing number of pregnancies, so the
team also examined the brains for signs of the disease. Of
the 59 women, 33 had Alzheimer’s disease. Compared to
healthy controls, fetal cells were found to be less common
in the brains of women who had Alzheimer’s disease. That
correlation suggests that the presence of fetal cells in the
maternal brains helps protect women against Alzheimer’s
disease. (PhillipsSep, et al. 2017)
Conclusion
The placenta is unique because it allows for intimate contact between maternal and fetal cells at the maternal-fetal interface throughout pregnancy. (Than et al.) During
pregnancy, the semi-allogeneic fetus is protected from
rejection by the maternal immune system. (Trowsdale and
Betz) It was hypothesized that the semi allogeneic fetus
could survive due to the regulation of the immunologic
interactions between mother and fetus. Such regulation
can be caused by functional suppression of the maternal
immune response or a lack of fetal antigen expression.
(Morelli et al.)
In the human placenta, fetal trophoblast cells do not
express MHC HLA-A and B molecules, which are responsible for allograft rejection in humans. (Chen et al.)
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Mixed hematopoietic chimerism, the state in which bone
marrow hematopoietic stem cells from two genetically
different animals coexist, remains the most robust tool
for tolerance induction. Unfortunately, bone marrow
or hematopoietic stem cell transplantation for patients
awaiting solid organ transplantation remains at highrisk, due to the dangers of graft-versus-host disease.
(Zavazava) Human embryonic stem cells express low
levels of (MHC)-I antigens and lack expression of MHC-II
antigens. These stem cells must engraft in the transplant
recipient, inducing tolerance to foreign cells, and reducing
the immune targeting of the transplant. Upon injection
into immunocompetent mice, human embryonic stem
cells are unable to produce an immune response. Human
embryonic stem cells may provide a potential tool for the
induction of immunotolerance. Further studies in human
embryonic stem cells immunobiology are warranted and
may reveal unique mechanisms that account for the immunological properties of human embryonic stem cells.
(Menendez et al.)
Fetal cells and DNA go beyond the womb and into
maternal blood and tissues during pregnancy and can last
long after birth. In some instances, fetal microchimerism
contributes to perturbations in maternal immunity that
may contribute to autoimmune diseases. In other cases,
these interactions seem to benefit long-term maternal
health by allowing fetal microchimerism cells to act as
allogeneic surveyors in her system. Fetal microchimerism has potential implications for the understanding of
women’s health and disease pathology postpartum. The
pregnant mother mshould never be viewed as merely an
incubator. Rather, microchimerism expands the biological
bonds that are established between the pregnant mother
and her fetus.
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